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                                                     ABSTRACT 
 
Self-amplifying mRNAs (SAM) based vaccines are effective at eliciting potent and 
protective immune responses. The SAM technology is developed as a platform 
technology with the potential to be used for a broad range of targets, able to 
induce both cellular and humoral response. Recently published data demonstrate 
that bone marrow derived Antigen Presenting Cells (APCs) are responsible for 
CD8 T cell priming after SAM vaccination, even though these cells are not able to 
express antigen directly from the SAM construct. This suggests cross-priming is a 
key mechanism for antigen presentation by SAM vaccines. Professional APCs are 
a key target for strategies aimed to enhance the immunogenicity of vaccines 
because of their specific ability to capture, process and present Ags to T cells. 
One successful approach for targeting these APCs is to increase the number of 
antigen loaded APCs at the injection site.  
Since GM-CSF is a chemoattractant for APCs, we developed a SAM(GM-CSF) 
vector and administered it intramuscularly in mice together with another SAM 
construct encoding the influenza A virus nucleoprotein [SAM(NP)]. We 
hypothesized that the presence of GM-CSF together with the NP antigen would 
lead to increased APCs recruitment and to an increased NP-specific CD8 T cell 
response. We indeed observed that administration of the SAM(GM-CSF) vector 
enhances the recruitment of APCs (DCs and macrophages or monocytes) in the 
draining lymph nodes and at injection site. Moreover, co-administration of 
SAM(GM-CSF) with SAM(NP) significantly improves the magnitude of NP-induced 
CD8 T-cell responses both in frequency of cytotoxic CD8+ T cells and in functional 
activity in an in vivo cytotoxicity assay.  
A second strategy addressed in the present study, in order to enhance the potency 
of SAM vaccines, is to target the antigen of interest directly to surface receptors 
expressed on cross-presenting DCs. Fusion constructs are made of single chain 
fragment variable (scFv) or ligands that bind surface receptors expressed on DCs 
fused to OVA antigen. These fusion constructs have been designed, expressed 
and tested in vitro for their binding activity to DCs. 
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INTRODUCTION 
 
Nucleic Acid Vaccines  
 
A key advancement in vaccinology has been the use of Vectors based on 
recombinant viruses (viral vectors). Safe and efficacious virus, such as vaccinia or 
adenovirus, are genetically modified in order to include genes encoding for 
immunogenic proteins from other pathogens and induce specific immunological 
responses against these antigens in vivo [1]. Viral vectors show several 
advantages over traditional vaccine technologies: they offer an efficient delivery of 
nucleic acid to the host cell using pathways of entry employed by the pathogen. In 
this way vectors mimic a live viral infection, with reduced safety risks associated 
with live organisms. Some of them are also able to deliver antigens directly to 
components of the immune system such as antigen presenting cells [2]. Moreover, 
they have intrinsic adjuvant effects due to the expression of pathogen associated 
molecular patterns which activate innate immunity. The main drawback of viral 
vectors is that the effectiveness of the vaccine may be reduced by pre-existing or 
vaccination-induced  immunity to the viral envelope [3].  
As an evolution of viral vectors, nucleic acid-based vaccines have emerged as 
alternative platform. They involve direct immunization with DNA or RNA encoding 
the antigen, which is synthetized in situ, and inducing an immune response 
directed only toward the antigen of interest. Both DNA and RNA-based vaccines 
do not generate immunity to the envelope, can be used for multiple doses, and are 
easy to produce, reducing manufacturing cost [2]. 
DNA (deoxyribonucleic acid) vaccination uses antigen-encoding DNA plasmid to 
produce an immunological response. This DNA plasmid can induce an immune 
response against parasites, bacteria and viruses [4, 5, 6]. The expression of the 
antigen-encoding gene can be increased by adding various promoters, enhancers 
and other elements to the backbone of plasmid DNA [4, 5, 7]. More than two 
decades of research studies have already demonstrated the effectiveness of 
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plasmid DNA vaccines to elicit antibody and T cell-mediated protection in animal 
models. However, DNA-based vaccines still have some limitations due to the weak 
immunogenicity in humans compared to small animal models [8, 9] and for the 
potential risk of DNA integration into the host genome.  
For these reasons, RNA-based vaccines have emerged as a safer and more 
potent alternative to DNA vaccines. 
 
 
RNA-based vaccines 
 
RNA-based vaccines have emerged as a promising alternative to plasmid DNA for 
gene vaccination [2, 10, 11]. RNA vaccines show some clear advantages over 
plasmid DNA. Unlike DNA, RNA is delivered directly into the host cytoplasm where 
it is translated avoiding the limiting step of crossing the nuclear membrane and the 
potential risk of genome integration. Moreover, RNA is produced in vitro using a 
cell-free enzymatic transcription reaction, avoiding safety concerns associated with 
the use of living organisms or anti-vector immunity associated with the use of viral 
vectors [12, 13]. 
RNA Vaccines show also an intrinsic adjuvant activity by activating members of 
the Toll Like receptors family that can induce innate immune responses, involving 
type I interferons (IFNs) [14, 15, 16].   
Currently, there are two major forms of RNA vaccines: conventional non-
amplifying mRNA molecules and self-amplifying mRNA, characterized by a 
replicative activity, derived from RNA viruses.  
Non-amplifying RNAs consist of a cap structure, an open reading frame encoding 
the gene of interest flanked by a 5’ and 3’ untranslated regions (5’ UTR and 3’ 
UTR), and a tail of adenosine residues (poly(A) tail) (Figure 1). They offer the 
advantages of the small size (2-3 kb), the simplicity of the construct and the 
absence of additional proteins, which excludes the possibility of undesired 
responses. However, non-amplifying mRNAs are poorly immunogenic in vivo [17], 
10 
 
probably because of their short half-life and instability that result in low level of 
antigen expression. Self-amplifying mRNAs were developed with the aim to extend 
the duration and magnitude of expression of the antigen of interest.  
Self-amplifying mRNAs, also called replicons, are derived from either positive- or 
negative-stranded RNA virus like alphaviruses (Sindibis, Semliki Forest, and 
Venezuelan equine encephalitis viruses) or flaviviruses (Yellow fever, Kunjin) [18, 
19, 20, 21, 22]. Self-amplifying mRNAs contain the basic elements of conventional 
mRNAs as described above, a large ORF encoding four nonstructural proteins 
(nsP1-4) that allow the amplification of the RNA, and a subgenomic promoter 
upstream of the gene of interest (GOI) that replaces the genes encoding the viral 
structural proteins, avoiding the production of infectious viral particles (Figure 1). 
RNA replicons are effective at eliciting humoral and cell-mediated immune 
responses in different animal models including mice [17], non-human primates 
[23], and humans [24], and they have been tested against several target diseases. 
The main disadvantage of RNA-based vaccines is their instability. Therefore, one 
of the most important challenges for RNA-based vaccines is to find effective 
delivery systems in order to prevent RNA enzymatic degradation and to facilitate 
the transfection of host cells. RNA replicons can be packaged into virus-like 
particles by supplying the structural proteins in trans in cell culture. These viral 
replicon particles (VRPs) are unable to produce new infectious particles and are 
effective at inducing potent immune responses in different animal models and 
humans, however, their clinical application is limited by safety concerns related to 
cell culture production. Therefore, several means of non-viral delivery have been 
explored, including inorganic particles, polymeric-based vectors and cationic lipid-
based vectors, or physical methods such as electroporation and gene gun delivery 
[25].  
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                                                                                 Deering RP et al, Expert Opin Drug Deliv 2014 
 
Figure 1 
Structural elements of RNA-based vaccines 
Schematic illustration of a conventional non-amplifying mRNA (upper figure) containing the cap 
structure, the 5’ UTR region, an open reading frame encoding the gene of interest (GOI), 3’ UTR 
and a poly(A) tail, and of a self-amplifying mRNA (lower figure) derived from an alphavirus genome, 
containing the basic elements described above, an ORF encoding four non-structural proteins 
(nsP1-4), and a subgenomic promoter upstream to the GOI. [26] 
 
 
 
SAM Vaccines  
 
The SAM Vaccine platform, first developed by Novartis Vaccines and later 
acquired by GSK Vaccines, is based on the non-viral delivery of a synthetic, self-
amplifying mRNA. This 9-kb self-amplifying mRNA is derived from an engineered 
alphavirus genome containing the genes encoding the alphavirus RNA replication 
machinery [27] whereas the structural protein sequences are replaced with genes 
encoding protein antigens, which are abundantly expressed from a subgenomic 
promoter in the cytoplasm of cells transfected with these self-amplifying RNAs 
(Figure 2) [28, 29, 30].  
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Figure 2 
Self-amplifying RNA derived from an alphavirus  
Scheme showing a self-amplifying RNA derived from an alphavirus in which structural genes have 
been replaced by the gene of interest 
 
The RNA is produced in vitro by an enzymatic transcription reaction from a 
linearized pDNA template using a T7 RNA polymerase.  
 
 
 
To provide protection from degradation, and to facilitate entry into cells, a non-viral 
delivery of self amplifying mRNA was explored. Geall and colleagues took 
advantage of a clinically suitable delivery system for short interfering RNA (siRNA) 
based on the use of synthetic lipid nanoparticle LNP [31, 32]. Cationic lipids and 
mRNA are mixed together to obtain stable particles that prevent RNA enzymatic 
degradation and deliver the mRNA into host cells by interacting with the negatively 
charged cell membrane (Figure 3).  
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Figure 3  
SAM Vaccines LNP formulates  
Schematic illustration of a lipid nanoparticle (LNP) encapsulating self-amplifying RNA Lipid 
components and relative functions are indicated. 
 
 
 
Once in the cytoplasm, the RNA polymerase, encoded by the non-structural genes 
of the viral replicon, is expressed and produces a negative-sense copy of the 
genome that is used as template for the amplification of the genome, as well as for 
the transcription of the sub-genomic mRNA encoding the vaccine antigen (Figure 
4). Encapsulation of the self-amplifying RNA in LNPs was shown to protect it from 
enzymatic degradation, assure efficient RNA delivery after intramuscular injection 
and increase the immunogenicity compared to injection of naked (unformulated) 
RNA [33].  
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Figure 4  
Schematic illustration of the steps in replication and expression of self-amplifying 
RNA after delivery to a mammalian cell. 
(1) Delivery of RNA to thecytoplasm. (2) Translation of the ORF encoding the four nonstructural 
proteins that form the RNA-dependent RNA polymerase (RDRP), which produces a negative-sense 
copy of the genome. (3) RDRP catalyses production of positive-sense genomes from the negative 
sense copy. (4) RDRP catalyses transcription of subgenome. (5) Translation of the gene of 
interest, leading to protein expression. 
 
 
 
An alternative non-viral delivery system is based on a cationic nanoemulsion 
(CNE), which binds to the SAM RNA, enhances its delivery, and thereby 
substantially increases the potency of the vaccine. CNE is composed of the 
cationic lipid DOTAP (1,2-dioleoyl-sn-glycero-3-phosphocholine), chosen for its 
previous clinical use and fixed positive charge, emulsified with the constituents of 
the emulsion adjuvant MF59, which is currently licensed in 30 countries and is well 
tolerated in children and adults. CNE was demonstrated to be an effective system 
able to induce immune responses in multiple animal species, including rhesus 
macaques, at comparable levels to responses elicited by an adjuvanted subunit 
vaccine or VRP delivery of the same RNA, and at doses much lower than those 
required for pDNA vaccines [25]. 
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The discovery that lipid-based formulations could be used to deliver self-amplifying 
mRNA vaccines brought a completely new approach to vaccine production using a 
simple, synthetic, rapid and cell-free process. These attributes make the SAM 
technology an attractive rapid response platform for the health challenges of the 
21st century. 
 
 
                                                                    Brito LA et al, Mol Ther 2014 
 
Figure 5 
SAM Vaccines CNE formulated 
Schematic illustration and role of components of CNE in complex with SAM RNA. 
 
 
 
Mechanism of action  
 
SAM vaccines demonstrated to induce functional immune responses against 
different infectious targets in multiple animal models, including non-human 
primates (NHPs). Preclinical proof of concept has so far been achieved for 
Influenza, Respiratory syncytial virus, Rabies, Ebola, Cytomegalovirus, Human 
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immunodeficiency virus and Malaria [33, 34, 25, 35]. However, little has been 
published on the mechanism of action of these vaccines. Recently published 
studies show that myocytes appear to be the predominant cell type transfected 
after SAM immunization but are not able to prime CD8 T cells; while it seems that 
bone marrow-derived professional APCs do not express directly the antigen but 
are required for the in vivo priming of MHC class-I restricted CD8 T cells. 
Therefore, a possible mechanism suggests that APCs could acquire the antigen 
from transfected myoblasts, implicating cross-priming as a mechanism for priming 
CD8 T cell response by SAM vaccines. However, the cellular mechanism by which 
cross-priming occurs in vivo still needs to be clarified. One hypothesis is that 
transfected cells at the site of injection undergo apoptosis during RNA 
amplification, leading to the release of the antigen associated apoptotic bodies, 
which are then phagocytosed by APCs and presented via MHC class-I restricted 
pathway. The published data strongly suggests cross-presentation by APCs of 
myocyte-derived antigens is the primary mechanism for priming CD8 T cells. 
However it cannot be excluded that some APCs are directly transfected by SAM 
vaccines but express the antigen under the limit of detection of the assays used in 
the studies [36]. 
 
 
 
Cross-priming and cross-presentation 
 
CD8+ cytotoxic T lymphocytes (CTLs) play a pivotal role in the immune defence 
against intracellular pathogens or tumours. These cells recognize tumor- or 
pathogen-derived antigenic peptides associated with MHC class I molecules, 
which are expressed on the surface of all cells in the body. When effector CTLs 
detect the specific peptide being presented by an infected or cancer cell, they 
destroy the cell to avert the spread of infection or cancer. The endogenous MHC 
class I pathway is reserved for peptides derived from intracellularly synthesized 
proteins. Naive antigen-specific CD8+ T cells need to be activated by professional 
antigen-presenting cells (APCs), usually dendritic cells (DCs), before they can 
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exert their cytotoxic effector functions. So when an intracellular pathogen does not 
directly infect APCs or when a tumour is not APC-derived (which is the case for 
most tumours), naive antigen-specific CD8+ T cells can only be activated by an 
APCs presenting the exogenous antigen on MHC class I molecules. This process, 
termed cross-presentation, was named after the phenomenon of cross-priming 
discovered in the 1970s by Bevan [37], in which antigens from intravenously 
injected cells 'crossed' into the MHC class I pathway of host APCs for CTL 
priming. Cross-priming has been shown to be required for defence against many 
viruses and tumours [38, 39], and it is essential for vaccinations with protein 
antigens, which must be cross-presented to activate CTLs [40] (Figure 6). Under 
normal circumstances, cross-presentation is probably less efficient than direct 
presentation, since cross-presentation requires the additional step of transfer from 
one cell to another. Apoptotic cells have been reported to be a good antigen 
source for cross-presentation in vitro [41, 42, 43], and recent studies also show a 
role for necrotic cells [41, 44] (Fig.6). 
 
 
 
 
 
 
 
 
 
 
                                                                                    Kaufmann SHE, Nat Rev Microbiology 2007  
 
 
Direct 
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Cross-priming 
Macrophage 
Bacterium 
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Draining lymph node  
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Figure 6 
Antigen presentation to different T-cell subsets: direct presentation and cross-
priming. 
Direct antigen presentation leads to unrestricted stimulation of CD4
+
 T cells, T cells and CD1-
restricted T cells. However, some bacteria have developed evasion mechanisms that impair direct 
antigen presentation. As most bacterial pathogens reside in the phagosome, direct major 
histocompatability complex (MHC) class I presentation of antigen for CD8
+
 T cells is impaired. Only 
bacterial pathogens that egress into the cytosol allow for direct antigen presentation to CD8
+
 T 
cells. Cross-priming was originally described as a pathway that allows MHC class I presentation of 
exogenous antigens to CD8
+
 T cells. It was later extended to include antigen presentation from 
bacterial pathogens.  
 
 
 
Roles of APC types in cross-priming.  
 
 
Despite the discovery of cross-priming in the 1970s, the phenotype of the APC 
responsible for this process remained unknown for long time.  
Bevan and colleagues [45] provided the first evidence that CD8a+ DCs are 
responsible for cross-priming in vivo in mice. Although CD8+ DCs now seem to be 
the predominant cross-presenting subset, it has been shown that under 
inflammatory conditions also DCs that lack the expression of CD8a can cross-
present, suggesting that this mechanism is influenced by the surrounding 
environment. Recent studies have proposed, as a possible mechanism, that cross-
presentation takes advantage of distinct endocytosis pathways able to introduce 
the antigen directly into the organelle (or organelles) in which cross-presentation 
occurs [46]. In support of this, it has been shown that the uptake of antigens for 
cross-presentation is restricted to distinct endocytosis receptors, such as Fc 
receptors and certain members of the C-type lectin receptor family, such as C-type 
lectin 9A (CLEC9A; also known as DnGR1), CLEC7A (also known as dectin 1), 
DC-SIGN (also known as CD209), DEC205 (also known as CD205) , mannose 
receptor 1 (also known as CD206) and XC-chemokine receptor 1 (XCR1) [47, 48, 
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49, 50, 51]. These receptors are expressed by CD8α+ DCs [46], providing a 
possible mechanistic explanation for why this DC subset can cross-present.  
 
 
 
 
GM-CSF 
 
Following intramuscular injection of SAM vaccine, most antigen expression occurs 
in transfected myocytes at the inoculation site. However, recent evidence suggests 
that T cell priming is initiated by professional APCs rather than myocytes [36]. 
Since professional APC are not typically found in normal muscle tissue, they 
presumably migrate to the site of inoculation in response to inflammatory or 
chemotactic signals. Then, infiltrating APCs present the SAM expressed antigen 
by both direct and cross presentation to initiate immune responses. Since APCs 
are present in low number at the injection site, to enhance antigen uptake by DCs, 
and therefore presentation, one of the strategies that has proven to be successful 
in the literature is to increase the number of antigen-loaded APCs at the injection 
site. For this purpose, GM-CSF has received considerable attention given its 
ability to enhance cellular immune responses specific for a variety of antigens. 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic 
cytokine responsible for the proliferation, differentiation, and activation of 
macrophages, neutrophils, and various APCs [52, 53, 54]. GM-CSF is produced 
by various cell types, including T cells, B cells, macrophages, mast cells, 
endothelial cells, fibroblasts, and adipocytes, in response to cytokine or 
inflammatory stimuli. GM-CSF can stimulate and enhance the production and 
function of neutrophils and monocytes. The adjuvant activity of GM-CSF is partly 
mediated by chemo-attraction and activation of APCs, which triggers antigen 
internalization, processing and presentation to lymphocytes [55]. Furthermore, by 
increasing the number and maturation state of DCs and by promoting their ability 
to cross-present antigens, GM-CSF can enhance the immune responses to 
vaccines (Figure 7). GM-CSF was first identified as an adjuvant for antitumor 
vaccines. Dranoff and colleagues reported that irradiated tumor cells transfected 
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with the gene encoding murine GM-CSF increased protection in mice upon 
immunization [56]. Subsequently, GM-CSF has been used as a vaccine adjuvant 
in a number of immunization systems; as a recombinant protein, GM-CSF has 
been injected locally or systemically [57, 58, 59, 60, 61] or in conjunction with 
hydrogel [62, 63]; dendritic cells (DCs) have been cultured in the presence of 
recombinant GM-CSF [64, 65] or transfected with the GM-CSF gene [66] and used 
to immunize mice [64, 66] or humans [65]; and plasmid-encoded GM-CSF (pGM-
CSF) has been used for DNA vaccination studies with the GM-CSF gene either 
linked to an Ag-encoding gene [67] as a bicistronic plasmid [68] or as a separate 
plasmid mixed with the Ag encoding plasmid [69, 70, 71, 72, 73, 74]. 
 
 
 
 
                                                                        Kaufman et  al, J. Immunotherapy of Cancer 2014 
 
Figure 7  
Immunobiologic effects of GM-CSF 
Effects of GM-CSF on cells of the immune system   
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Targeting Antigens to Dendritic Cells receptors 
 
The superior ability of cross-presenting  DCs to stimulate adaptive immunity 
suggests that an enhanced immune response could be gained from targeting 
antigens directly to this DCs population in vivo [75, 76]. The most widely studied 
approach involves the selective targeting of DCs by linking the antigen of interest 
to antibodies (in the form of either monoclonal antibodies or single chain variable 
fragment, scFv) or ligands that specifically bind to their endocytic receptors. 
Following internalization by the targeted DCs, the intracellular routing of these 
complexes depends on the specific receptor targeted, and has functional 
consequences regarding the antigen presentation and T cell stimulation (Figure  
8). 
Targeting antigens to DCs-specific receptors may reduce the required vaccine 
dose and reduce the portion of the vaccine dose that ends up in non-target cells, 
thus diminishing potential adverse effects. To date, more than 100 DC-targeting 
studies have been published [77]. The first DC-targeting studies in mice were 
aimed at Fcγ receptors (FcγRs), MHC class II molecules and CD40 [78, 79, 80], 
and showed that antigen targeting improves both humoral and cellular adaptive 
immunity. During the last decade, research has focused on C-type lectins and, in 
particular, CD205 (also known as LY75) has been extensively studied in mice, 
NHPs and humans. 
DEC-205 is a C-type lectin that delivers ligands to late endosomal/lysosomal 
compartments and it has been proven to be especially effective at inducing CD8+ 
T cell responses [81]. This suggests that antigen-targeting to DEC-205 might be 
useful for inducing protective CTL-based immunity in diseases such as cancer, 
malaria, and HIV. 
As CD8α+ DCs are superior at cross-presentation, targeting this DC subset is 
advantageous for inducing CD8+ T cell responses. The human orthologue of this 
DC subset lacks CD8α, but expresses CLEC9A, XCR1 and blood DC antigen 3 
(BDCA3; also known as CD141 and thrombomodulin) [82, 83, 84, 85, 86]. In 
particular, the ability of CLEC9A and XCR1 to target CD8α+ DCs in mice makes 
these receptors the most promising candidates for the induction of CTL responses. 
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                                                                                                  Kastenmüller W et al., Nat Rev Immunology 2014 
 
 
Figure 8 
Antigen presentation and intracellular routing.  
Targeting antigens via surface receptors leads to internalization of the receptor together with its 
cargo. The intracellular routing depends on the receptor and has important functional 
consequences for antigen presentation. Most receptors are routed to late endolysosomes in which 
antigen is quickly degraded and efficiently presented on MHC class II molecules to CD4
+
 T cells. 
Some receptors route their cargo to early endosomes in which antigen is slowly digested, leading 
to prolonged MHC class I presentation to CD8
+
 T cells [87] [88] [89]. Thicker arrows indicate that 
the pathway of antigen presentation is more efficient. 
 
 
 
 
 
 
 
Antigen linked to 
targeting antibodies  
MHC class I vs class II presentation  Intracellular routing 
Receptor that routes 
cargo to early endosomes 
upon binding to the 
targeted vaccine 
Receptor that routes 
cargo to late endosomes 
upon binding to the 
targeted vaccine 
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                                  RATIONAL AND AIM 
 
SAM vaccines are emerging as a promising technology platform able to generate 
potent, versatile and easily produced vaccines to address the health challenges of 
the 21st century [66, 67, 70, 71, 79]. 
The mechanism by which SAM vaccines activate the host immune system has not 
been deeply investigated. Recently published data suggests that bone marrow 
derived Antigen Presenting Cells (APCs) are responsible for CD8 T cell priming 
after SAM vaccination. Since muscle fibers express antigens after SAM 
immunization, but APCs are not directly transfected by the SAM construct, cross-
priming is proposed as the key mechanism for antigen presentation by SAM 
vaccines.  
The aim of the current study was to explore strategies to further potentiate the 
SAM platform. Assuming the pivotal role of APCs for the induction of the immune 
response, and taking into account the low amount of APCs present at the injection 
site, we wanted to investigate 2 different strategies to enhance the immune 
response induced by SAM vaccine: on one side by increasing the recruitment of 
APCs at the site of injection and on the other side to target the antigen specifically 
to DCs. 
In the literature, the enhancement in the number of APCs has been obtained in 
different ways and using different chemoattractants; in particular, GM-CSF has 
been selected among different possible molecules as an important hematopoietic 
growth factor and immune modulator  
Our first aim was to investigate whether an increase in the number of Antigen 
presenting cells at the injection site could improve the immunogenicity to a model 
antigen by using GM-CSF expressed by SAM vector as chemoattractant.  
The model antigen chosen for the study was Ovalbumin protein and later on the 
Nucleoprotein from Influenza A Virus was used to obtain more complete data on 
the immunogenicity and to investigate also the effect of SAM(GM-CSF) on the 
protective efficacy after an Influenza challenge.  
24 
 
A secondary aim of the present study was to evaluate whether targeting 
specifically the antigen of interest to DCs, we could obtain an increase in the 
immune response. The targeting is obtained by using fusion constructs made of 
scFV or ligand that bind surface receptors expressed on DCs , and fused to OVA 
antigen. 
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                                MATERIALS AND METHODS 
 
 
Cloning and RNA synthesis of vaccine antigens  
 
Mouse GM-CSF coding sequence (Gene ID: 12981) was codon optimized for 
expression in mouse by GeneArt. The synthetic gene was amplified using forward 
primer 5’-acatagtctagtcgacgccaccatgtg-3’ and reverse primer 
5’gggcgtagcggcggccgctgggtgggcgcgccg-3’. The coding sequence of GM-CSF was 
mutated at amino acids 15 (H to A) and 21 (E to A) by PCR SOEing using the 
following primers: forward primer 5’-
gccgtggaagccatcaaagccgccctgaacctgctggacgac-3’ and reverse primer 5’-
ggctttgatggcttccacggccttccagggtctggtcacgg-3’. This mutant form of GM-CSF 
(mutGM-CSF) has lost the ability to bind to the GM-CSF receptor and lacks 
bioactivity [74, 90] . 
The SAM (NP) construct was described previously [36, 91]. 
The coding sequence of Ovalbumin (Gene ID: 100303699) was truncated from aa 
1 to 144, to obtain a cytosolic expression, as described elsewhere [92]. The 
sequence was PCR amplified by using forward primer 5’-
tctagtcgacgccaccatgttccagacagctgccga-3’ and reverse primer 5’-
cgtagcggcggccgctggtcagggtgacacgcagcg-3’. 
All the amplicons were then cloned as a Sal I and Not I fragment into the SAM 
vector. 
Plasmid DNA encoding NP, Ovalbumin, GM-CSF and mutGM-CSF were amplified 
in Escherichia coli and purified using the Qiagen Plasmid Maxi kit Endo free 
(Qiagen). DNA was linearized immediately downstream the 3’ end of the replicon 
by endonuclease digestion with Pme I for NP and OVA, with BspQ I for GM-CSF 
and mutGM-CSF, and purified by phenol/chloroform extraction and ethanol 
precipitation. Linearized DNA templates were transcribed into RNA using the 
MEGAscript T7 transcription kit (LifeTechnologies), following manufacturer’s 
instructions, and purified by LiCl precipitation. RNA was then capped using the 
ScriptCap m7G Capping System (CellScript) and purified again by LiCl 
26 
 
precipitation. RNA was resuspended in RNAse free water and its integrity was 
evaluated on 1% denaturing agarose-LE gel (Ambion). 
For protein purification, GM-CSF and mutGM-CSF sequences were cloned into a 
pCMV vector with a 6-His tag at the C terminus. SAM vector encoded sequences 
were PCR amplified with forward primer 5’-agtctagtcgacgccaccatgtg-3’ and 
reverse primer 5’- atatctagattagtgatggtgatggtgatgcttctggccgggtttcttgc-3’ and then 
cloned as Sal I and Xba I fragments  into a pCMV expression vector.  
 
 
RNA vector self-amplification and protein expression assessment 
 
Baby hamster kidney cells (BHK, ATCC) were cultured in Dulbecco’s modified 
Eagle’s 
medium (Gibco, Carlsbad, CA) containing 5% fetal bovine serum (Euroclone) at 
37°C and 5% CO2, and used at 80% confluence at the time of transfection. 
To determine the efficiency of RNA self-amplification, 1x106 trypsinized BHK cells 
were electroporated (120V, 25ms pulse) with 200 ng of RNA and incubated for 
16–18 h at 37°C and 5% CO2. Cells were then stained with Live/Dead Aqua 
(Invitrogen), fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences), and 
stained with APC-conjugated anti-double stranded (ds) RNA antibody (J2 
monoclonal mAb mouse IgG2a kappa chain, Bioclass). Anti-dsRNA IgG2a was 
conjugated using the Zenon Allophycocianin labeling kit (Invitrogen). For NP 
protein expression, an anti-NP antibody conjugated to FITC (Thermo Fisher) was 
used. Frequencies of dsRNA+ cells and NP+ cells were measured by flow 
cytometry on a FACS CANTO II flow cytometer (BD Biosciences). 
 
For Western blot analyses, 16-18h post-transfection supernatants were collected 
and BHK cells were trypsinized and lysed in 1X Loading sample buffer (Novagen). 
Supernatants and whole cell lysates of 2x105 cells were subjected to SDS-PAGE 
under reducing conditions and blotted to nitrocellulose membranes. GM-CSF and 
mutGM-CSF were detected with a polyclonal rabbit anti-mouse GM-CSF antibody 
(1:2500 dilution; Abcam), Ovalbumin with a polyclonal rabbit anti-Ovalbumin 
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(Abcam), followed by horseradish peroxidase-conjugated goat anti-rabbit IgG 
secondary antibody (1:5000 dilution; Dako). Protein bands were visualized by 
chemiluminescence following manufacturer’s instructions (GE Health Care, Life 
sciences).  
The supernatants of BHK cells transfected with SAM (GM-CSF) were subjected to 
PNGase treatment 1h at 37° in order to check the glycosylation pattern of the 
expressed GM-CSF. 
 
 
 
Expression and Bioactivity of GM-CSF  
 
Expi 293T cells were transfected with pCMV encoding GM-CSF His-tagged protein 
and mutGM-CSF His-tagged, according to manufacturer’s instructions. 
Supernatants were collected 48 h after transfection and tested for protein 
expression by Western Blot analysis. A combination of polyclonal rabbit-anti-GM-
CSF (Abcam) and goat-anti-rabbit-HRP (Dako) antibodies was used for detection. 
Both proteins were purified from supernatants of transfected cells by Ni-NTA-
affinity chromatography as described by the manufacturer (Qiagen).  
The ability of the purified GM-CSF to generate DCs from bone marrow cultures 
was tested. Bone marrow derived monocytes (BM-DCs) were induced from BM 
cells obtained from 5-6 weeks-old C57Bl/6 mice as previously described [93]. 
Briefly, a single cell suspension was prepared from BM obtained from femurs. 
2x106 BM cells were cultured in RPMI 1640 medium (Gibco) supplemented with 25 
mM HEPES (Gibco), 10% heat inactivated FBS (low endotoxin, HyClone), 1x 
Pen/Strep/Glut (100x, Gibco), 50 μM β-mercaptoethanol (Sigma) and 10 ng/ml His 
tagged mouse GM-CSF (a mouse recombinant GM-CSF from Miltenyi was used 
as a positive control at the same concentration) in 10 cm diameter Petri dishes at 
37 °C in 5% CO2. Supplemented medium was replaced every three days. On day 
8, non-adherent cells were collected and analyzed by FACS. The differentiated 
cells were characterized by surface staining with the antibodies anti-CD80 
PECF594, anti-CD86 FITC (all BD Bioscience), anti-CD11c APCeFluor780, anti-
F4/80 eFluor450 and anti-Gr1 PercPCy5.5 (all eBioscience) in FACS analysis. 
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Mice  
 
Animals were housed in the GSK Vaccines Animal Facility and experiments were 
conducted in compliance with the ARRIVE guidelines, the current Italian legislation 
(Legislative Decree 116/92), and with the GSK Animal Welfare Policy and 
Standards. 
Female C57Bl/6 mice (Charles River Laboratories, Calco, Italy), aged 5–6 weeks, 
were immunized intramuscularly (i.m.) on day 0 in the quadriceps muscles of both 
hind legs (25 μl vaccine formulation per leg) with 1.5 μg of each formulated RNA, 
in combinations described in details for each experiment.  
 
CNE/RNA formulation  
 
CNE was prepared as previously described [25]. Each RNA was formulated 
independently as follows: RNA was diluted in the appropriate buffer at a 
concentration of 300 μg/ml and was then added to an equal volume of CNE. The 
complex was mixed gently and allowed to complex on ice for 30 min. Prior to 
administration, formulations were diluted to dosing concentrations and mixed when 
indicated. Formulations were characterized for particle size and RNA integrity 
(using gel electrophoresis) as previously described [25]. Dynamic light scattering 
was used to determine CNE particle size. CNE was diluted 1:500 in PBS and 
added to disposable low volume cuvettes (Malvern). Samples were measured on a 
Malvern NanoZs Zetasizer with a backward angle measurement using “PBS” as a 
dispersant (RI = 1.330). For RNA integrity, the RNA were extracted from the 
CNE56 by addition of 25 μl formulated sample to 475 μl isopropanol (Sigma). After 
30 minutes of centrifugation at maximum speed, the pellet was suspended in 
nuclease free water (Ambion) and 1X Glyoxal Loading Dye (Ambion). The RNA 
were analyzed by gel electrophoresis on mini gel (MOPS/Sodium Acetate/EDTA 
buffer) 1% agarose and run at 100V.  
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Immune cell infiltrate in quadriceps muscles and draining lymph nodes   
 
C57Bl/6 mice aged 5–6 weeks (eight mice per group) were inoculated in the 
quadriceps muscles of the two hind legs (25 µl per site) on day 0. On day 1, 2, 3, 
4, 7, 10, 25 mice were sacrificed and both of the quadriceps muscles and draining 
inguinal lymph nodes were collected. Quadriceps muscles and lymph nodes were 
then dissociated into single cell suspensions and analyzed by flow cytometry for 
immune cell infiltrate composition. To obtain single cell suspension, quadriceps 
muscles were digested with the enzyme mix provided by the Skeletal Muscle 
Dissociation kit (Miltenyi) for 1h at 37 °C under constant agitation. The resulting 
cell suspensions were centrifuged, resuspended in Dulbecco's modified Eagle's 
medium (Gibco) and filtered through 70 μm nylon mesh (BD) before staining. 
Lymph nodes were dissociated by using a mix of Liberase DL research 
Grade (Roche) and DNAse I (Sigma) for 90 minutes at 37 °. The resulting cell 
suspensions were filtered through a 30 μm filter and then washed with PBS before 
staining. The single cell suspensions, from muscles and lymph nodes were stained 
with Live Dead Yellow (Invitrogen) and the following fluorescently labeled 
antibodies: anti-Ly6C FITC, anti-CD11b PE-Cy7, anti-Ly6G PE, anti-CD8 α APC, 
(all from BD Pharmingen) and anti-MHCII AlexaFluor700, anti-F4/80 eFluor450, 
anti-CD11c APC-AlexaFluor780, (all from eBioscience) and anti-
CD3PerCPCy5.5(BD Biosciences). The stained cells were acquired on a LSR II 
Special Order System flow cytometer (BD Biosciences) using BD DIVA software 
(BD Bioscience). The different cell subsets were identified following the gating 
strategy shown in Figure 9 and 10. 
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Figure 9 
Gating strategy for the identification of cells recruited in the muscles after SAM 
administration. 
Live cells were negatively selected based on Live/Dead dye exclusion, and immune cells 
were further identified based on morphology. After discrimination of singlets, CD11b+ cells 
were selected. Among them, neutrophils are identified as double positive for Ly6C and 
Ly6G expression. After exclusion of NPh, Dendritic cells (DCs) cells were selected as 
MHCII+/CD11c+. 
After exclusion of DCs, monocytes , macrophages and eosinophils were identified.  
Lymphocytes were selected based on morphology and among them T (CD3+/MHCII-), B 
(CD3-/MHCII+) and NK (CD3-/MHCII-) cells were discriminated.  
Representative dot plots are shown. 
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Figure 10 
Gating strategy for the identification of cells recruited in the lymph nodes after SAM 
administration. 
Live cells were negatively selected based on Live/Dead dye exclusion, and immune cells 
were further identified based on morphology. After discrimination of singlets, CD11b-
/Cd11c- cells were selected. Among them B cells were identified as CD3-/MHCII +, while 
T cells as CD3+/MHCII -. On CD11b+/CD11c+, Dendritic cells (DCs) cells were selected as 
MHCII+/CD11c+. After exclusion of DCs, neutrophils (Nph) were visualized based on Ly6C 
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and Ly6G expression. After exclusion of Nph, monocytes were identified as LY6C+ F480int 
and macrophages (Mph) as Ly6Clow int/F4/80+.  
 
 
 
Determination of cytokine concentration in sera  
 
At indicated time points after the immunization, sera samples were collected. A 
panel of 23 cytokines, both pro-inflammatory and anti-inflammatory, were 
evaluated using the Luminex Bio-Plex Pro Mouse Cytokine 23-Plex Immunoassay 
(Bio-Rad), according to the manufacturer's protocol. 
 
 
ELISA  
 
NP-specific, OVA-specific or GM-CSF-specific IgG titers were determined on sera 
collected 3 weeks after the immunization. 96–well Maxisorp plates (Nunc) were 
coated with 0.26 μg/well of NP Protein (Sinobiological), 0,1 μg/well of OVA protein 
(Sigma) or 0,1 μg/well of GM-CSF protein(Miltenyi) at 4°C overnight. On the next 
day, plates were washed with PBS/0.05% Tween 20 and blocked with PBS/1% 
BSA for 2 h at room temperature. Serum samples and a standard serum were 2-
fold serially diluted in PBS, 1% BSA, 0.05% Tween 20, then transferred into 
coated and blocked plates and incubated 2 h at RT. Plates were washed and 
incubated with an alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma) 
for 2 h  at room temperature. Then the P-nitrophenyl phosphate substrate was 
added and the reaction was stopped by using 3% EDTA pH 8. Absorbance was 
measured with an Infinite M200 plate reader (Tecan) at 405 nm. The IgG titers 
were normalized with respect to the standard serum assayed in parallel and are 
indicated as ELISA Units/ml (EU/ml). 
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Spleen processing  
 
Spleens were harvested from C57Bl/6 mice 10 days after immunization and 
placed in 5 ml of cold RPMI 1640 medium (Gibco) supplemented with 25 mM 
HEPES (Gibco), 2% heat inactivated FBS (Euroclone) and 1x Pen/Strep (100x, 
Gibco) in a 15 ml tube. Spleens were dissociated using the pestle of a 5 ml syringe 
through a 70 μM cell strainer placed on top of a 50 ml Falcon tube. Red blood cells 
were lysed by incubating the cell pellet with 1 ml of lysis buffer (eBiosciences) for 3 
min at room temperature. The reaction was stopped by adding 9 ml of RPMI. After 
centrifugation at 300 x g for 5 minutes, splenocytes were suspended in 4 ml of 
medium: RPMI 1640 (Gibco) supplemented with 25 mM HEPES (Gibco), 10% 
heat inactivated FBS (low endotoxin, HyClone), 1x Pen/Strep (100x, Gibco) and 
50 μM β-mercaptoetanol (Sigma). Cell suspension was filtered on a 30 μm strainer 
and cell counts determined using an hemocytometer. 
 
 
 
 
Intracellular cytokine staining (ICS)  
 
To assess antigen-specific T-cell responses, single-cell suspensions were 
prepared from spleens of immunized mice as described above. 2x106 splenocytes 
were plated in 96w plates together with anti-CD28 mAb (2 μg/ml; Pharmingen), 
anti CD-49 mAb (2 μg/ml; eBioscience) and with anti-CD107a FITC conjugated 
(2.5 μg/ml; BD Biosciences). Cells were stimulated for 6 h with H2-Db-restricted 
NP peptide ASNENMETMESS (2.5 μg/ml; JPT), or with the recombinant NP 
protein (5 μg/ml; Sino Biological Inc.), or with H-2Kb-restricted (SIINFEKL) or I-Ad-
restricted (ISQAVHAAHAEINEAGR) OVA peptides (InvivoGen) all diluted in 
reaction medium. The same number of cells was incubated with anti-CD3 mAb 
and anti-CD28 mAb (Pharmingen, 1mg/ml each) as positive control. Brefeldin A (5 
μg/ml; Sigma) was added for the last 4 h. For flow cytometry analyses, cells were 
stained with Live/Dead Near InfraRed (Invitrogen), fixed and permeabilized with 
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Cytofix/Cytoperm (BD Biosciences), and then incubated with anti-CD16/CD32 Fc 
block (BD Biosciences). Cells were further stained with anti–CD4 V500 
(eBioscience), anti-CD3 APC, anti–IFN-γ+ Brilliant Violet 785, anti–IL-2 PE-Cy5.5, 
anti–TNFα+ Brilliant Violet 605 (All from Biolegend), anti–CD44 V450 (BD 
Horizon), and anti-CD8 PE Texas Red (Invitrogen). Samples were acquired on a 
LRSII special order (BD Biosciences), and analyzed using FlowJo software 
version 9.9.5 (LLC). T cells were identified following the gating strategy shown in 
Figure 11. Frequencies of antigen-specific T cells were calculated after subtracting 
the background measured in the corresponding negative control (incubated with 
medium only) for each cytokine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 
Gating strategy for flow cytometry analyses of CD4 and CD8 T-cell responses 
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Live cells were negatively selected based on dye exclusion, and lymphocytes were further 
identified based on morphology. CD3+ T cells were selected after discrimination of singlets 
and CD4 and CD8 T cells were  
identified based on CD4+ and CD8+ expression, respectively. Cytokine+ (IFN-γ, IL-2 and 
TNFα) and CD107a+ cells were identified among the CD4+CD44high and CD8+CD44high T 
cell subsets.  
Representative dot plots are shown. 
 
 
 
 
In vivo cytotoxicity assay 
  
Groups of 6 C57Bl/6 mice were immunized as described above. To prepare target 
cells, spleens from naïve mice were processed as described above and 
splenocytes were split into two populations. One population was pulsed for 1 h at 
37°C with 5 μM of NP366-377 peptide (ASNENMETMESS), washed, and labeled 
with 0.5 μM of CFSE for 15 min at RT (CFSE+ cells). The other population was 
pulsed with an unrelated OVA257-264 peptide (SIINFEKL), and labeled with 10 μM of 
CMTMR for 30 min at 37°C (CMTMR+ cells). An equal number of cells (4 x106 
total splenocytes) from the two different peptide-pulsed and labeled populations 
was mixed and injected intravenously into immunized mice 10 days after the first 
immunization. After 18 h, mice were sacrificed and collected splenocytes were 
stained with Live dead Near InfraRed and then analyzed on a LRSII Special order 
System (BD Biosciences) to determine the frequencies of CFSE+ and CMTMR+ 
cells. 
The percentage of target cell killing was determined as previously reported [94] : 
100 − ((percentage of peptide-pulsed targets in immunized mice/percentage of 
unpulsed targets in immunized mice)/(percentage of peptide-pulsed targets in PBS 
control mice/unpulsed targets in PBS control mice) × 100). 
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Influenza virus challenge  
 
Four weeks after the immunization, anesthetized mice were challenged 
intranasally with a 
lethal dose of  Influenza A Virus PR8 (H1N1) (38.5 TCID50) mouse-adapted 
influenza virus (15 μl per nostril). Survival, body weight, and clinical signs of illness 
(e.g. ruffled fur, hunched posture, hypothermia, body weight loss, wheeze) were 
monitored daily for 2 weeks after the infection. A clinical score of 4 and a body 
weight loss superior than 25 % of the initial weight were defined as humane 
endpoint; animals meeting these criteria were euthanized.  
 
 
Statistical analysis  
 
Statistical analyses were performed using GraphPad Prism 7.0 software. 
Experiments involving animal survival were analyzed by Mantle-Cox Log-rank test. 
For the other statistical analyses, Mann-Whitney U test was used. P values less 
than 0.05 were considered statistically significant. *, P<0.05; **, P<0.01; ***, 
P<0.001. 
 
 
 
Cloning and purification of fusion constructs 
 
The expression constructs encoding the fusion constructs to target OVA antigen to 
DCs were obtained as follows. To generate scFv anti DEC-205-OVA and scFv anti 
Clec9a-OVA, the cDNA of the heavy and light chain variable regions of the 
monoclonal antibody NLDC-145 (US 2004/0146948) and of the monoclonal 
antibody 10B4 (US 8,426,565) respectively were assembled with a (Gly4Ser)3 
encoding linker and synthesized by GeneArt. The sequences were amplified by 
PCR from the GeneArt constructs to yield 750 bp long single-chain fragments. The 
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scFvs were fused to OVA full length coding sequence by PCR SOEing (scFv anti-
DEC205-OVA and scFv anti-Clec9a-OVA), separated by a glycine serine linker 
(GSGGGG). XCL1-OVA was obtained by fusing the full length murine XCL1 
coding sequence (Gene ID: 16963) to OVA full length, separated by the glycine-
serine linker. To try to improve the binding of the 3 different fusion proteins to DCs, 
OVA coding sequence was put at the N-terminus of each construct (OVA-scFv 
anti-DEC205, OVA-scFv antiClec9a and OVA-XCL1). A 6-His tag was added at 
the C-terminus of each of the fusion construct to facilitate the detection and 
purification. The resulting products were then cloned into a pCMV expression 
plasmid containing a murine Ig k chain leader sequence. Supernatants collected 
from Expi293 T cells transfected with 30 µg of each fusion construct expression 
plasmids were subjected to affinity chromatography purification by using Ni-NTA 
columns. Protein production and purification were analyzed by SDS PAGE gel 
electrophoresis and Western blotting using an anti-OVA antibody.  
 
 
 
In vitro binding assay 
 
To evaluate the binding of the fusion proteins to DCs, spleens from naïve C57Bl/6 
mice were collected and processed as described above. 3x106 cells were washed 
with PBS and incubated for 30 minutes at 37° with the different fusion constructs 
to test (30 µg/ml each). As negative control, the cells were incubated with OVA 
protein only. Cells were washed with PBS 3 times and incubated on ice for 30 
minutes with an anti-OVA-FITC conjugated antibody. The cells were washed again 
3 times with PBS and then stained on ice with anti-CD11c-APCe780 conjugated, 
anti-MHCII A700 conjugated, anti-CD8a PECF594 conjugated antibodies for 30 
minutes. After 2 washes with PBS, mouse DCs were identified by FACS as 
CD11c+ and MHCII+ cells. Gating on these DCs, we identified the CD8+ DCs and 
among them the cells positive for the anti-OVA antibody. 
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                               RESULTS 
 
PART I  
 
Generation and in vitro characterization of SAM constructs 
 
To determine whether an increased number of Antigen presenting cells at the 
injection site could improve the immunogenicity to a model antigen, GM-CSF was 
selected as chemoattractant. For this purpose, GM-CSF was cloned in the SAM 
vector: briefly the mouse GM-CSF coding sequence was codon optimized for 
expression in mouse by GeneArt and amplified by PCR from the synthetic gene. A 
control plasmid encoding a non-active form of mouse GM-CSF (altered at two 
amino acids, 15 and 21, required for binding to the GM-CSF receptor) was 
constructed by PCR SOEing. The NP gene was amplified from the reverse-
transcribed RNA genome of influenza virus A/PR/8/34. The coding sequence of 
Ovalbumin was truncated from aa 1 to 144 and then PCR amplified. All the 4 
different genes were cloned using Sal I Not I restriction sites into the SAM DNA 
plasmid backbone containing the promoter for the T7 bacteriophage RNA 
polymerase (Figure 12, a). 
Linear plasmid DNAs were transcribed into RNA through the in vitro transcription 
reaction and a guanine nucleoside (cap) was added to the 5' terminus of primary 
RNAs with the in vitro capping system as reported in Materials and Methods. The 
quality and the integrity of purified RNAs were assessed by agarose gel 
electrophoresis: bands of the expected molecular weight (9Kb) and no signs of 
degradation were observed (Figure 12, b). 
The self-amplification capability of the replicons was evaluated in vitro in BHK cells 
(Baby Hamster Kidney) transfected (by electroporation) with 200 ng of each RNA 
to test, or with the same amount of a control RNA of known potency (STD). An 
anti-double strand RNA antibody was used to detect the percentage of cells 
positive for a replicating RNA by flow cytometry (Figure 12, c). The frequencies of 
dsRNA+ BHK cells after transfection with SAM (GM-CSF), or SAM (mutGM-CSF), 
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or SAM (NP) or SAM (OVA) were even higher than that obtained with the STD, 
indicating that the new replicons self-amplified appropriately. 
 
a) 
 
 
 
b)                                                                        c) 
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Figure 12 
Schematic representation of self-amplifying RNA vectors and their characterization 
in vitro 
(a) SAM(GM-CSF), SAM(mutGM-CSF),SAM(NP) and SAM(OVA) constructs, derived from 
an alphavirus genome, contain a 5’ cap, four nonstructural genes (nsp1-4), a 26S 
subgenomic promoter (blue arrow), the vaccine antigen and a 3’ polyadenylated tail. 
(b) The integrity of the in vitro synthesized RNAs was confirmed by electrophoresis on an 
agarose gel. RNA ladder (lane 1), RNA after (lane 2) the capping reaction. 
(c) Self-amplification capability of SAM vectors was assessed by flow cytometry. The 
graph shows the percentage of cells containing replicating SAM vectors (dsRNA+ cells).  
 
 
 
 
To evaluate antigen expression, BHK cells were further transfected with 1 µg of 
each replicon; cell lysates and supernatants were analyzed by Western Blot 
(Figure 13, a and b) for the expression of OVA, GM-CSF and mutGM-CSF, 
respectively, while NP expression was evaluated by flow cytometry (Figure 13, d). 
GM-CSF and mutGM-CSF were detected in the supernatant by using an anti GM-
CSF antibody. Both proteins appear as 3 bands, one of the expected molecular 
weight of 14 kDa, as the positive control (commercial recombinant protein 
produced in E. coli), and the other 2 of higher molecular weight (about 18 and 24 
kDa). GM-CSF is a highly glycosylated protein (2 N-glycosylation sites and 2 O-
glycosylation sites); to verify whether the higher molecular weight bands were due 
to N-glycosylation, the protein from the supernatant was treated with PNGaseF for 
1h at 37°. After the treatment, the highest molecular weight bands disappear, 
confirming the correct glycosylation pattern (Figure 13, c). The truncated form of 
OVA protein was detected in the cell lysate by using an anti-OVA antibody. The 
protein appears as a band of the expected molecular weight of 40 kDa.  
For NP protein, an anti-NP FITC conjugated antibody was used to detect NP by 
flow cytometry. The percentage of NP expressing cells was comparable to that of 
a Standard SAM NP of known potency, and correlated to the % of dsRNA+  cells.  
 
 
41 
 
 
     a)                                                      b)                                                       c) 
 
 
 
 
 
 
 
 
d)   
                                                                     
 
Figure 13 
Replicons efficiently express the target antigens. 
Efficiency of antigen expression by BHK cells transfected with synthesized RNAs was 
evaluated by Western blotting (a, b, c) and flow cytometry (d).  
Western blot analysis with anti-GM-CSF antibody of supernatants from BHK cells mock 
transfected or transfected with a SAM(GM-CSF) or SAM(mutGM-CSF) vector. A 
commercial mouse GM-CSF protein was used as positive control. (c) Western blot 
analysis of GM-CSF protein from supernatant of BHK cells transfected by SAM GM-CSF, 
before and after treatment with PNGase F. (d) Flow cytometry analysis of SAM(NP) (left) 
or mock (right) transfected BHK cells after intracellular staining with anti-NP FITC 
conjugated antibody. 
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In vitro biological characterization of GM-CSF and mutGM-CSF  
 
In order to characterize the biological activity of GM-CSF and mutGM-CSF, the 
coding sequences of both molecules were cloned into a pCMV plasmid with a 6-
His tag at the C-terminus. Expi 293 T cells were transfected with the plasmids and 
48 hours after transfection, expression of the recombinant proteins was detected 
in cell supernatants by Western Blot analysis. The proteins were then purified from 
supernatants via Ni2+-NTA columns and analyzed by SDS PAGE (Figure 14).  
 
 
 
 
 
                                                          
Figure 14  
Purification of GM-CSF and mutGM-CSF expressed from Expi 293 T cells for in vitro 
characterization  
SDS-PAGE of GM-CSF and mutGM-CSF purified from supernatants of Expi 293 T cells. 
 
 
 
Bone marrow derived monocytes (BMDM) can be differentiated into immature DCs 
by co-culture with GM-CSF. The ability of the purified GM-CSF to generate 
Dendritic cells from BMDM was compared to a commercial, recombinant form of 
GM-CSF used as positive control (Miltenyi). After 8 days of culture, BM derived 
cells were analyzed by FACS to evaluate the % of CD11c+/Gr1- and 
CD11c+/CD80+ cells. Recombinant GM-CSF and the purified His tagged GM-CSF 
were equally efficient in generating DCs from BMDM (Figure 15). The positive 
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control was able to induce 68% of CD11c+/Gr1- cells and 62 % of CD11c+/CD80+ 
cells, the his-tagged GM-CSF induced 70% of CD11c+/Gr1- cells and 74 % of 
CD11c+/CD80+ cells). On the contrary, BMDM in the presence of the mutant form 
of GM-CSF died after 3 days, indicating that it was not biologically active; in fact, in 
the absence of a specific stimulus of survival and growth, the primary cells died. 
 
 
 
 
 
 
 
Figure 15  
Ability of GM-CSF to generate DCs from BMDM 
The graphs show the percentage of differentiated DCs after 8 days in culture with GM-
CSF (right panels) or a recombinant GM-CSF (left panels). Differentiated DCs were 
identified as CD11c+/Gr1- cells or CD11c+/CD80+.  
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Characterization of CNE formulation 
 
  
For the in vivo studies, the cationic nanoemulsion (CNE) was selected as non-viral 
delivery system, in particular SAM replicons were formulated with CNE56 [25] in a 
1:1 ratio. Each RNA was formulated independently with CNE56 and then the 
formulated RNAs where mixed when indicated. In this way each RNA can be 
characterized singularly. Mean particle size and polydispersity were measured by 
dynamic light scattering for SAM(GM-CSF)/CNE, SAM(mutGM-CSF)/CNE, 
SAM(NP)/CNE and SAM(OVA)/CNE. Z-average diameters ranged from 133 to 
137 nm with a polydispersity index of approximately 0,120 (Figure 16). The 
formulated SAM were also tested for pH and osmolality; the pH ranged between 
6.5 and 7 and osmolality was around 360 mOsm for all the formulations. The 
analyzed critical quality attributes, included pH, osmolality, particle size and RNA 
integrity, were all in compliance with the specifications and within acceptance 
ranges. 
RNA integrity after isopropanol extraction from CNE56 was evaluated by 1% 
agarose gel electrophoresis. The extracted RNAs show no products of 
degradation (Figure 17).   
 
 
 
 
Figure 16 
Characterization of SAM/CNE56 formulations 
Particle size (Z-average diameter) and polydispersity index were evaluated for each 
RNA/CNE formulation. 
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Figure 17 
Evaluation of the integrity of SAMs after extraction from CNE56  
Agarose gel electrophoresis showing the integrity of the 4 different RNAs after extraction 
from CNE56.  
 
 
 
In vivo recruitment of immune cells at the injection site and in the draining 
lymph nodes after SAM immunization  
 
The mechanism of action of SAM vaccines is characterized by a cellular infiltrate 
in the muscle after immunization. To study whether SAM(GM-CSF) was able to 
increase the recruitment of immune cells in vivo, mice were immunized with 
different SAM combinations and  cells from muscles and draining lymph nodes 
from the differently treated mice were analyzed by flow cytometry.  
In a first set-up experiment, mice were immunized with SAM(OVA) + SAM(GM-
CSF) while control mice were immunized with SAM(OVA) + SAM(GFP): it is 
known that CNE per se is able to induce cell recruitment [25], for this reason 
SAM(GFP) was added to SAM(OVA) in the negative control group as unrelated 
RNA, in order to administer the same dose of total formulated RNA to the different 
treatment groups. Immune cell recruitment was assessed from 3 hours to 3 days 
after the immunization in quadriceps muscles and inguinal draining lymph nodes. 
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Single cell suspensions were stained with a variety of antibodies to lineage and 
activation markers followed by flow cytometry.  Mice immunized with SAM(GM-
CSF) showed a significant increase in the number of immune cells that progressed 
from day 2 to day 3. In particular, monocytes, macrophages, eosinophils and 
dendritic cells are the populations that show a high increase (Figure 18, a). While 
for the control group the peak of recruitment was observed at day 2 and started to 
decrease at day 3, for mice immunized with SAM(OVA) + SAM(GM-CSF) the 
recruitment was still raising 3 days after administration.  
Based on these results, a second experiment was performed in order to assess 
the recruitment at longer time points, with 25 days after the immunization as the 
last time-point evaluated. In this experiment, SAM(GFP) was replaced by 
SAM(mutGM-CSF), a more appropriate negative control: mice were immunized 
with SAM(OVA) + SAM(mutGM-CSF) or SAM(OVA) + SAM(GM-CSF). Immune 
cells infiltration was assessed at different time points after the immunization. At 
day 3, 4 and 7 after the immunization, mice immunized with SAM(OVA) + 
SAM(GM-CSF) showed a stronger cellular infiltrate compared to the group 
immunized with SAM(OVA) + SAM (mutGM-CSF) (Figure 18, b) . In particular, 
despite the number of infiltrating cells were different in the two groups, the cellular 
composition did not differ significantly.  
There was an increase of monocytes, macrophages and dendritic cells at day 2 in 
both groups, but while in the group of mice that received mutGM-CSF the 
recruitment of these cells stopped and the numbers went down, in mice treated 
with GM-CSF the recruitment went on until day 4. The increased number of 
dendritic cells, macrophages, and monocytes in mice immunized with SAM(OVA) 
+ SAM (GM-CSF) show a peak at day 4 and then start to decrease. At day 7, all 
cell number returned to base line level, except for dendritic cells that are still 
present in the muscle in higher number compared to the control group. At 10 and 
24 days after injection, cell numbers were comparable to that of naïve mice. The 
same effect was observed when mice were immunized with SAM(NP) instead of 
SAM(OVA) (Figure 18,c). From figure 18, it is clear that the majority of cells 
recruited were the APCs: a detailed analysis of the APCs subpopulation showed 
that macrophages and mDCs were recruited at day 3 and 4 in all the experiments 
in the groups immunized with SAM(GM-CSF) + SAM(NP) or OVA, while 
neutrophils and monocytes did not show an increase (Figure 19). 
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a) 
  
 
 
 
b) 
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c) 
 
 
 
Figure 18 
Characterization of cell recruitment in quadriceps muscles following SAM 
immunization 
Quadriceps muscles, both left and right, (n=4) were collected at different time points after 
the immunization to evaluate cellular composition. Bars represent the total number of cells 
recruited into the muscles, and colors indicate the different cell types; a) mice immunized 
i.m. with 1.5 µg SAM(OVA) + 1.5 µg SAM(GFP) or with 1,5 µg SAM(OVA)+ 1.5 µg 
SAM(GM-CSF); b) mice immunized i.m. with 1.5 µg SAM(OVA) + 1.5 µg SAM(mutGM-
CSF) or with 1,5 µg SAM(OVA)+ 1.5 µg SAM(GM-CSF); c) mice immunized i.m. with 1,5 
µg SAM(NP)+ 1.5 µg SAM(mutGM-CSF) or with 1,5 µg SAM(NP)+ 1.5 µg SAM(mutGM-
CSF) 
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Figure 19 
Kinetic of the recruitment of inflammatory cells in quadriceps muscles  
Kinetic of neutrophils, monocytes, macrophages, and DCs are indicated for each 
experimental group; a) mice immunized with SAM(OVA) + SAM(mutGM-CSF) or with 
SAM(OVA)+ SAM(GM-CSF); b) mice immunized with SAM(NP)+ SAM(mutGM-CSF) or 
with SAM(NP)+ SAM(mutGM-CSF). Statistical analysis was performed using the Mann-
Whitney U test: * p < 0.05; ** p < 0.01.  
 
 
 
 
 
 
Cell recruitment was analyzed also at the level of the inguinal draining lymph 
nodes of the immunized mice.  
 Differently from what observed in the injection site, no significative difference was 
observed between the immunization groups in total number of cells recruited in the 
inguinal draining lymph nodes,  regardless of the model antigen used (Figure 20 a, 
b and c). A detailed analysis of cell populations revealed a statistically significant 
increase in the number of monocytes recruited at day 3 for SAM(NP) and at day 4 
for SAM(OVA) in mice injected with SAM(GM-CSF) in comparison with mice 
injected with SAM(mutGM-CSF) (Figure 21 a and b). 
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Figure 20 
Characterization of cell recruitment in draining lymph nodes following SAM 
immunization 
Inguinal draining lymph nodes, both left and right, (n=4) were collected at different time 
points after the immunization to evaluate cellular composition. (a) Bars represent the total 
number of cells recruited into the muscles, and colors indicate the different cell types: a) 
mice immunized i.m. with 1.5 µg SAM(OVA) + 1.5 µg SAM(GFP) or with 1,5 µg 
SAM(OVA)+ 1.5 µg SAM(GM-CSF); b) mice immunized i.m. with 1.5 µg SAM(OVA) + 1.5 
µg SAM(mutGM-CSF) or with 1,5 µg SAM(OVA)+ 1.5 µg SAM(GM-CSF); c) mice 
immunized with 1,5 µg SAM(NP)+ 1.5 µg SAM(mutGM-CSF) or with 1,5 µg SAM(NP)+ 1.5 
µg SAM(mutGM-CSF).  
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b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 
Kinetic of the recruitment of inflammatory cells in draining lymphnodes  
Kinetic of neutrophils, monocytes, macrophages, and DCs are indicated for each 
experimental group; a) mice immunized with SAM(OVA) + SAM(mutGM-CSF) or with 
SAM(OVA)+ SAM(GM-CSF); b) mice immunized with SAM(NP)+ SAM(mutGM-CSF) or 
with SAM(NP)+ SAM(mutGM-CSF). Statistical analysis was performed using the Mann-
Whitney U test: * p < 0.05; ** p < 0.01.  
 
 
 
 
Immunogenicity to SAM(OVA) and to SAM(NP) 
 
To assess whether the enhanced recruitment of APCs induced by SAM(GM-CSF) 
has an impact on immunogenicity,  in a first, set-up experiment C57Bl/6 mice were 
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SAM(OVA)+ 1,5 µg SAM(GM-CSF). The immunogenicity to OVA antigen was 
evaluated both at the cellular and humoral level. 
Antigen-specific T-cell response was characterized by intracellular staining (ICS) 
and flow cytometry (Figure 22 a and b): antigen-specific, cytokine-secreting cells 
were identified among CD44high CD8+ and CD4+ T cells following the gating 
strategy showed in figure 11. 10 days after immunization, splenocytes derived 
from immunized mice were stimulated in vitro either with the MHC class I (H-2Kb)-
restricted peptide epitope of ovalbumin OVA257-264 peptide, the MHC class II (I-Ad)-
restricted peptide epitope of ovalbumin OVA323-339 peptide or with the recombinant 
OVA protein.  
OVA-specific CD8+ T-cells frequencies ranged around 0,4% for SAM(OVA)+ 
SAM(GFP) immunized mice, and 0,7% for mice immunized with SAM(OVA)+ 
SAM(GM-CSF)(Figure 22, a). The majority of OVA-specific CD8+ T-cells were 
IFN-γ+ or IFN-γ+/TNFα+ in both treatment groups; SAM(GM-CSF) was therefore 
able to induce an increase in the total number of CD8+ T-cells but did not change 
the quality of the response. OVA-specific CD4+ T-cells were not detectable, 
independently from the stimulus used (OVA323-339 peptide or recombinant OVA 
protein), in none of the immunization groups (Figure 22, b). 
OVA-specific antibody titers were analyzed by ELISA: no IgG were detectable in 
sera collected 3 weeks after immunization in none of the immunization groups 
(data not shown); this data were in line with the CD4+ T-cells response results.  
 
 
a)                                                           b) 
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c)                                                                  d)  
                                               
 
 
Figure 22 
T-cell responses induced by SAM formulations 
(a - b) C57Bl/6 mice were immunized i.m. once with 1,5 µg of SAM(OVA)+ SAM(GFP), or 
with SAM(OVA)+SAM(GM-CSF). Ten days after the immunization, 4 mice per group were 
sacrificed, an intracellular staining and FACS analysis were performed on splenocytes 
stimulated in vitro with the OVA147-155 peptide (a) or with the recombinant OVA protein (b). 
Graphs show the cumulative frequency of antigen (Ag)-specific, cytokine-secreting CD8+ 
(a) or CD4+ (b) T cells, and the color code indicates the different type of cytokine 
produced by the respective cells, as indicated. In c) and d) the frequency of total Ag-
specific cytokine secreting CD8+ T cells and CD4+  T cells, respectively.  
 
 
 
 
 
The same kind of analysis was performed to assess the impact of SAM (GM-CSF) 
on NP immunogenicity. C57Bl/6 mice were immunized i.m. either with 1,5 µg of 
SAM(NP), or with 1,5 µg of SAM(NP) + 1,5 µg SAM(mutGM-CSF) or with 1,5 µg of 
SAM(NP) + 1,5 µg SAM(GM-CSF). The antigen-specific T-cell response was 
assessed 10 days after the immunization: splenocytes were stimulated in vitro with 
the MHC class I-restricted peptide epitope NP147-155 (Figure 23, a) or with 
recombinant NP protein (Figure 23, b). 
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The frequencies of NP-specific CD8+ T-cells ranged around 0.4 % of total CD8+ T-
cells for SAM(NP) and SAM(NP)+ SAM(mutGM-CSF) immunized mice, around 
0.8% in SAM(NP)+SAM(GM-CSF) immunized mice. As observed for 
immunizations performed using OVA as model antigen, the majority of NP-specific 
CD8+ T-cells were IFN-γ+ and IFN-γ+/TNFα+, characteristic of an effector 
phenotype.  
NP-specific CD4+ T-cells were detectable after one immunization and showed 
predominantly the Th0 phenotype (IL-2+/TNFα+, TNFα+, and IL-2+) or the 
multifunctional Th1 phenotype (IFN-γ+/IL-2+/TNFα+). As shown in figure 23 b, NP-
specific CD4+ T-cells induced by SAM(GM-CSF) were slightly but not significantly 
higher with respect to the other immunization groups.  
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Figure 23 
T-cell responses induced by SAM formulations 
(a - b) C57Bl/6 mice were immunized i.m. once with 1,5 µg of SAM(NP), or with 1,5 µg of 
SAM(NP)+ SAM(mutGM-CSF) or with SAM(NP)+SAM(GM-CSF). Ten days after the 
immunization, 6 mice per group were sacrificed, an intracellular staining and FACS 
analysis were performed on splenocytes stimulated in vitro with the NP147-155 peptide (a) or 
with the recombinant NP protein (b). Graphs show the cumulative frequency of antigen 
(Ag)-specific, cytokine-secreting CD8+ (a) or CD4+ (b) T cells, and the color code indicates 
the different type of cytokine produced by the respective cells, as indicated. In c) and d) 
the frequency of total Ag-specific cytokine secreting CD8+ T cells and CD4+  T cells, 
respectively. Representative data are the mean ± standard deviation (SD) of 6 mice from 
each group and were analyzed by Mann-Whitney U test: * p < 0.05; ** p < 0.01.  
 
 
 
The humorale response to NP was evalueted by assessing the presence of NP-
specific IgG in the sera of SAM-immunized mice. Mice that received 
SAM(NP)+SAM(GM-CSF) reached antibody titers comparable to those of mice 
vaccinated with SAM(NP) only or SAM(NP)+SAM(mutGM-CSF) (Figure 24). 
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Figure 24 
SAM(GM-CSF) has no effect on antigen-specific IgG 
Sera samples were collected 3 weeks post 1 immunization to determine NP specific IgG 
titers by ELISA. Statistical analysis was performed using the Mann-Whitney U test. 
 
 
 
 
 
SAM (GM-CSF) enhances the cytotoxic activity of CD8 T cells 
 
Finally, we characterized antigen-specific T cells induced by SAM vaccines for 
cytotoxic activity in vitro and in vivo (Figure 25).  
Antigen-specific T cell cytotoxicity was evaluated by measuring the surface 
expression of CD107a, as a measure of the degranulation process, upon in vitro 
antigen-stimulation of splenocytes derived from immunized mice. CD107a is a 
lysosomal membrane protein that is transiently expressed on the T cell surface as 
a result of the degranulation process and is associated with T cell cytotoxicity. The 
immunization with SAM(NP) + SAM(GM-CSF) induced a higher frequency of 
CD107a+ NP-specific CD8 T cells compared to the other treatments. The majority 
of NP-specific CD8+ T cells were CD107a+ for all the immunization groups (Figure 
25, a).  
To evaluate the in vivo cytotoxic activity of NP-specific CD8 T cells, an equivalent 
number of splenocytes derived from naïve mice were pulsed with the H2-Kd 
restricted NP147-155 peptide (and stained with 0.5 µM CFSE) or with an unrelated 
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OVA 257-264 peptide (and stained with 10 µM CMTMR). The two population were 
then mixed and adoptively transferred intravenously in mice immunized with either 
1,5 µg of SAM(NP), 1,5 µg of SAM(NP)+ 1,5 µg SAM(mutGM-CSF) or 1,5 µg of 
SAM(NP) + 1,5 µg SAM(GM-CSF). The percentage of CFSE+ and CMTMR+ cells 
present in the spleens were measured by flow cytometry 18 hrs after the adoptive 
transfer. In mice immunized with SAM(NP) or SAM(NP) + SAM (mutGM-CSF), an 
equal specific lysis of 84% was achieved (Figure 25, b). In the group immunized 
with 1,5 µg of SAM (NP) + 1,5 µg SAM(GM-CSF), we detected a specific lysis of 
98%, statistically significantly higher than the one observed in the other groups. No 
specific lysis was detected in PBS treated mice confirming the specificity of the 
cytotoxic activity. These results demonstrated that SAM(GM-CSF) is able to 
enhance the cytotoxic activity of the induced CD8 T cells in vivo. 
 
a)                                                                   b) 
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Figure 25  
SAM(GM-CSF) increases the cytotoxic activity of NP-specific CD8 T cells in vitro 
and in vivo 
(a) The surface expression of the CD107a marker was assessed. The bars show the 
percentage of cytokine secreting CD8 T cells that express (red bars) or not (blue bars) 
CD107a.  
(b) Spleens from mice immunized with SAM(NP) alone or in combination with 
SAM(mutGM-CSF) or SAM(GM-CSF) were collected 10 days after the first immunization 
to measure the induction of cytotoxic NP-specific CD8+ T cells by flow cytometry. The 
graphs show the percentage of NP-specific lysis calculated for each immunization group. 
Representative data are the mean ± standard deviation (SD) of 6 mice from each group 
and were analyzed by Mann-Whitney U test: * p < 0.05; ** p < 0.01. (c) Representative dot 
plots indicating the numbers of CMTMR+ and CFSE+ cells in each immunization group are 
shown.  
 
 
 
 
Administering SAM(NP) at the peak of APCs recruitment has no effect on the 
cellular response 
 
Considering that APCs recruitment at the injection site reaches a peak at day 4 
after the immunization, we wondered whether administering the SAM(NP) at the 
peak of recruitment could have a beneficial effect on the CD8 T cell response. For 
this purpose, mice were first immunized with SAM(mutGM-CSF), with SAM(GM-
CSF), or PBS 3 days before the administration of SAM(NP). 10 days after the 
administration of the antigen, intracellular cytokine staining was performed. The 
effect of increase in the CD8 T cell response observed when SAM(GM-CSF) was 
co-administered with SAM(NP), was lost when administering SAM(GM-CSF) 3 
days before. Indeed all the immunization groups reached the same percentage of 
CD8 T cells and no increase was observed in the group immunized with SAM(GM-
CSF) (Figure 26). We can therefore conclude that SAM(GM-CSF) better exerted 
its effect when it was co-administered with the antigen.        
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  a)                                                    b)  
                                                    
Figure 26 
The administration of SAM(GM-CSF) at the peak of APCs recruitment has no effect 
on the cellular response  
C57Bl/6 mice were immunized i.m. with PBS, or 1,5 µg of SAM(mutGM-CSF) or with 1,5 
µg of SAM(mutGM-CSF) or with SAM(GM-CSF). 3 days after SAM(NP) was administered 
to all groups of mice.Ten days after the immunization with SAM (NP), 6 mice per group 
were sacrificed, an intracellular staining and FACS analysis were performed on 
splenocytes stimulated in vitro with the NP147-155 peptide. Graphs show the cumulative 
frequency of antigen (Ag)-specific, cytokine-secreting CD8+T cells (a), and the color code 
indicates the different type of cytokine produced by the respective cells, as indicated (b). 
 
 
 
 
Effect of SAM (GM-CSF) treatment in protection against influenza virus 
challenge  
 
To explore the adjuvant effect of SAM(GM-CSF) on protection to Influenza A 
Virus, C57Bl/6 mice were immunized with 1.5 µg of SAM(NP), 1.5 µg of 
SAM(NP)+ 1,5 µg SAM(mutGM-CSF) or 1,5 µg of SAM (NP) + 1,5 µg SAM(GM-
CSF), and challenged with 38 TCID50 of influenza A/PR/8/34 (H1N1) virus. Animal 
weight was monitored for 14 days after the infection (Figure 27). 
Unexpectedly,  the PBS-treated control mice showed a higher survival rate (75%) 
and a more limited body weight loss at the peak of infection (10%), as compared 
to prior virus dose finding experiments (LD50, lethal dose 50). One possible 
explanation is that a change in the anesthesia technique, introduced in our animal 
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facility shortly prior to the experiments, altered the experimental settings. Thus, the 
virus needs to be re-titrated with the new infection conditions. The consequence of 
this low infection level is that mice immunized with the different combinations of 
SAM(NP) were all protected with a 100% survival rate and a very limited weight 
loss narrowing the window of experimental readout. Nevertheless, a trend of better 
fitness was observed for mice immunized with SAM(NP) + SAM(GM-CSF), in two 
independent experiments. 
 
 
 
Figure 27 
SAM(NP) containing formulations protect mice against lethal influenza challenge 
C57Bl/6 mice (16 mice/group) were immunized i.m. with 1,5 µg of SAM(NP),1,5 µg of 
SAM(NP)+ 1,5 µg of SAM(mutGM-CSF), or with 1,5 µg of SAM(NP)+ 1,5 µg of SAM(GM-
CSF). Four weeks after the injection, mice were challenged with 38 TCID50/mouse of 
homologous influenza virus A/PR8/34 (H1N1). Mice were monitored for body weight loss 
for 14 days post infection and euthanized if the body weight loss was superior than 20%. 
Graphs show mean of single mice ± SEM.  
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Reactogenicity analysis 
 
Levels of inflammatory cytokines and body weight were measured to evaluate if 
SAM (GM-CSF) treatment induced a reactogenic profile. A panel of 23 cytokines 
(pro-inflammatory and anti-inflammatory) was evaluated in the sera of immunized 
mice 1, 2, 3, days after the injection. The curve represents the mean of cytokine 
concentration as pg/ml + SD. We observed no difference in the level of 
proinflammatory and anti-inflammatory cytokines between mice immunized with 
SAM(OVA)+ SAM(GFP) and mice treated with SAM(OVA)+ SAM(GM-CSF) 
(Figure 28). Body weight loss was the parameter of choice as read-out of pain and 
discomfort or global impairment of health in small rodents [95]. Body weight was 
monitored in immunized mice along 4 days after the immunization. The mice from 
both groups did not show any severe body weight loss; on the contrary, they 
gained weight 2 days after the immunization (Figure 29). To further characterize 
the reactogenic profile, we wanted to exclude that the administration of SAM(GM-
CSF) induces autoantibodies antiGM-CSF. No antibodies anti GM-CSF were 
detected 3 weeks after the immunization, both for SAM(NP) +SAM(GM-CSF) and 
for SAM(OVA)+SAM(GM-CSF) immunized mice (Data not shown). We can 
conclude that SAM(GM-CSF) did not induce a reactogenic profile to be considered 
with caution.  
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Figure  28 
Cytokine evaluation  
Mice were immunized with SAM(NP) alone or in combination with mutGM-CSF or GM-
CSF. At the indicated time points, sera were evaluated for a panel of cytokine. The curves 
represent mean of cytokine concentration as pg/ ml + SD.  
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Figure  29 
Body weight loss evaluation  
Body weight of mice was monitored until day 4 after the immunization. The curves 
represent the mean+SD of body weight loss for each treatment group.   
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PART II 
 
 
Construction and expression of fusion contructs to target DCs 
 
In order to improve presentation of the antigen to T cells, therefore the immune 
response, we have explored the possibility to target the Antigen to 3 different 
receptors expressed on CD8+ DCs: DEC205, CLEC 9a and XCR1. To deliver 
antigen to these molecules, we cloned heavy and light chain variable regions from 
the monoclonal antibody to DEC205 and CLEC9a and genetically fused OVA with 
a glycine serine linker, obtaining scFv anti-DEC205-OVA and scFv anti-CLEC9a-
OVA respectively. To target XCR1, we cloned the coding sequence for XCL1, the 
specific ligand for XCR1, and fused to OVA (XCL1-OVA). A scFv anti-Nad A 
protein was fused to OVA and used as negative control for the experiments as it 
does not bind to DCs.  Alternative fusion constructs to target DCs were obtained 
by putting OVA at the N terminus of the construct (Figure 30). All the fusion 
constructs were transfected in Expi293 T cells. Expression and secretion of the 
constructs was evaluated by WB in supernatants of transfected cells. As shown in 
figure 31, all the fusion constructs appear on WB at the expected molecular weight 
in supernatants of transfected cells. The constructs were then purified by Ni-NTA 
to test them for binding to DCs. 
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Figure 30 
Design of fusion constructs to target DCs 
a)Heavy-chain (VH) and light-chain (VL) variable regions of each mAb anti DEC-205 and 
antiCLEC9a  were connected by an interchain linker (GGGGS)3 and cloned in frame 
upstream of the cDNA for OVA separated by a GSGGGG linker. b) OVA full length cDNA 
as cloned upstream of the scFv anti-DEC-205 and anti-CLEC9a. c) murine XCL1 cDNA 
was fused to OVA full length cDNA by a GSGGGG linker. d) OVA full length cDNA was 
cloned upstream of the XCL1 cDNA. 
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Figure 31 
Analysis of the expression of the fusion contructs 
Supernatants and cell lysates of Expi 293T cells transfected with expression plasmids for 
the different fusion constructs or mock transfected were Western blotted using  an Ab 
against OVA. 
 
 
 
 
 
In vitro targeting of antigen to DCs 
 
To verify that the fusion proteins were able to recognize the specific receptors 
expressed on target DCs, we measured specific binding to mouse splenocytes 
incubated with each construct. After the incubation, a secondary antibody to OVA-
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FITC conjugated was used to detect OVA-positive DCs, identified as 
CD11c+/MHCII+/CD8a+. We compared the binding activity of each fusion 
construct to its alternative form in which the OVA protein is at the N terminus. As 
shown in figure 32, OVA-scFv anti-DEC205 was able to bind better than scFv-
antiDEC205-OVA. The fusion constructs that should target CLEC9a receptors 
showed a very low binding activity. In particular scFv anti-CLEC9a seemed to be 
unable to bind the receptor, while OVA-scFv anti-CLEC9a barely binded to DCs. 
A higher percentage of OVA positive cells were found when cells were incubated 
with XCL1-OVA than with OVA-XCL1 (Figure 32). On the basis of this in vitro 
assay, we  selected OVA-scFv(anti-DEC205), XCL1-OVA and OVA-scFv(anti-
CLEC9a) as fusion constructs to be cloned in the next future into the SAM 
backbone and to be tested in vivo to evaluate whether they were able to induce an 
increase in the immunogenicity to OVA antigen. This approach has not been 
prosecuted because there was no more time to start the immunogenicity studies 
testing the different constructs.  
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Figure 32 
Binding of the different fusion constructs to DCs 
Binding to DCs of the different OVA fusion proteins was detected by an OVA-specific, 
FITC-labeled secondary antibody. Each of the 3 fusion construct was compared to its 
variant in which OVA is at the N-terminus for its binding activity. The dot plots represent 
the percentage of cells CD8+ and OVA positive among the CD11c/MHCII + cells.  
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                                               DISCUSSION 
 
SAM vaccines are emerging as a novel class of nucleic acid-based vaccines. They 
offer the advantage of being fully synthetic and to combine the positive attributes 
of live-attenuated vaccines, while avoiding some of their limitations. Self-amplifying 
mRNA vaccines are considered a promising technology platform able to generate 
potent, versatile and easily produced vaccines to address the health challenges of 
the 21st century [66, 67, 70, 71, 79]. 
The mechanism by which SAM vaccines activate the host immune system has not 
been deeply investigated. Recently published data suggests that bone marrow 
derived Antigen Presenting Cells (APCs) are responsible for CD8 T cell priming 
after SAM vaccination. Since muscle fibers express antigens after SAM 
immunization, but APCs are not directly transfected by the SAM construct, cross-
priming is proposed as the key mechanism for antigen presentation by SAM 
vaccines. Understanding the mechanism of action of these vaccines may enable 
to improve their efficacy.  
The aim of the current study was to explore strategies to further potentiate the 
SAM platform. Assuming the pivotal role of APCs for the induction of the immune 
response, and taking into account the low amount of APCs present at the injection 
site, we investigated the possibility to enhance the immune response induced by 
SAM after the first immunization by increasing the recruitment of APCs at the site 
of injection.  
In the last years this strategy has been deeply investigated and the enhancement 
in the number of APCs has been obtained in different ways and using different 
chemoattractants; in particular, GM-CSF has been selected among different 
possible molecules as an important hematopoietic growth factor and immune 
modulator and for its ability to induce maturation, migration, differentiation of 
Dendritic cells. GM-CSF has already been applied as immune adjuvant in many 
studies and in multiple vaccine platforms. 
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Our goal was to investigate whether an increase in the number of Antigen 
presenting cells at the injection site could improve the immunogenicity to a model 
antigen by using GM-CSF expressed by SAM vector as chemoattractant.  
The model antigen selected for the study was Ovalbumin protein in a preliminary 
phase of the project, while in a second phase we moved to the Nucleoprotein from 
Influenza A Virus, in order to obtain a more complete set of data on the 
immunogenicity and to investigate also the effect of SAM(GM-CSF) on the 
protective efficacy after an Influenza challenge.  
We have demonstrated that co-administration of SAM(GM-CSF) with SAM(OVA) 
is able to induce a significantly higher recruitment of immune cells compared to a 
combination of SAM(OVA)+ SAM(GFP). This recruitment was observed at the 
injection site, while in the lymph nodes small changes in cell numbers were 
detected.  SAM(GFP) , an unrelated RNA, was added to SAM(OVA) for the control 
group, since it was known that the RNA formulated with CNE56 was able itself to 
induce a recruitment of immune cells. The majority of cells recruited at the 
injection site were antigen presenting cells, in particular Dendritic cells, 
Macrophages and Monocytes. The recruitment was continuously raising along the 
time-course, until day 3 after the immunization, leaving open the question on the 
duration of this immune cells recruitment. For this purpose, another in vivo 
recruitment study was performed to evaluate the infiltration of immune cells at the 
injection site along 24 days after the immunization. We have also decided to use a 
more appropriate negative control for the experiment; instead of the GFP, we co-
administered with OVA a mutant form of GM-CSF that proved to be biologically 
inactive. The time course showed that the recruitment of APCs peaked at day 4 
after the immunization and then started to decrease at day 7 returning to baseline 
levels at day 10. At the level of draining lymph node, only the population of 
monocytes showed a significant increase at day 3 in the group of mice immunized 
with SAM(GM-CSF).  
 We next wanted to evaluate whether the enhanced recruitment of APCs at the 
injection site could be related to an increase in the immunogenicity. We showed 
that mice immunized with SAM(GM-CSF) + SAM (OVA) induced a higher % of 
OVA-specific CD8+ T cells compared to mice immunized with SAM(OVA) + 
SAM(GFP), 10 days after the immunization. We did not observe any OVA-specific 
CD4+ T cell response specific to, probably due to the low dose of SAM(OVA) 
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administered. This effect correlated to the Antibody response: no detectable IgG 
titers 3 weeks after the immunization. In order to better characterize the immune 
response after SAM(GMCSF) administration, we decided to repeat the set of 
experiments with another antigen: we selected the Nucleoprotein antigen, since it 
proved in our hands to have high antigen-specific CD8+ and CD4+ T-cell response 
as well as high antibody titers after one immunization with low doses of RNA. 
We confirmed the data previously obtained on the recruitment study with OVA as 
antigen also in mice immunized with SAM(NP) + SAM(GM-CSF) compared to 
mice immunized with SAM(NP) + SAM(mutGM-CSF). Indeed, the same trend of 
increase of the same populations was observed; thus, changing the antigen does 
not modify the effect of SAM (GM-CSF). The cellular immune response induced by 
SAM(GM-CSF) was assessed also for NP antigen. The co-administration of 
SAM(GM-CSF) with SAM(NP)  was able to induce a significant increase in the 
number of CD8+ T cells with a cytotoxic profile, compared to SAM(NP) + 
SAM(mutGM-CSF) co-administration or to SAM(NP) only administration. 
Moreover, we demonstrated that the cytotoxic CD8+ T cells induced by SAM(GM-
CSF) have an enhanced cytotoxic activity in vivo. 
At the level of NP-specific CD4+ T cells, only a slight increase was observed when 
mice were immunized with SAM(GM-CSF) + SAM(NP). This result was confirmed 
by the levels of NP-specific IgG titers. Indeed, SAM(GM-CSF) did not induce an 
increase in the Antibody titers. Moreover, on the basis of previous studies related 
to the timing of GM-CSF administration and its influence on the immune response, 
and considering the enhanced recruitment of APCs at day 3-4 after the 
immunization, we questioned whether the administration of SAM(GM-CSF) 3 days 
before the administration of the NP antigen, could further improve the presentation 
of the antigen and therefore potentiate the immune response. The data show that 
prior administration of SAM(GM-CSF) abolishes the increase on CD8+ T cells, 
thus suggesting that SAM(GM-CSF) better exerts its beneficial effect on the 
cellular response when it is co-administered with the antigen.  
Finally, we studied the protective efficacy induced by SAM(GM-CSF) after the 
Influenza challenge, but this topic has to be further investigated, since in two 
parallel experiments performed, mice from the control group showed a high 
survival rate (75%) and a limited body weight loss at the peak of infection (10%), 
suggesting a very modest infection level. Nevertheless, in both experiments a 
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trend of better fitness was observed in mice immunized with SAM(NP) + SAM(GM-
CSF) with respect to mice immunized with SAM(NP) or SAM(NP)+SAM(mutGM-
CSF). 
Overall, these findings suggest the adjuvant role of the SAM(GM-CSF) on the 
induction of the CD8+ T cell response; This suggest that the use of a chemo 
attractant that induces a recruitment of APCs at the injection site could help 
generating a stronger cellular response, probably acting on cross presentation. 
The increase in the number of Antigen presenting cells seems to have a beneficial 
effect especially on the cross presentation.  
Overall, these findings suggest that the co-administration of a chemoattractant, in 
this case GM-CSF, able to induce a recruitment of APCs at the injection site, could 
help in generating a stronger cellular response upon SAM vaccination, probably 
mediated by an enhancement of the antigen cross-presentation.  
In this study, we offered an alternative strategy to potentiate the SAM Vaccine 
Platform.  
Although the Platform has already proven to be efficient in inducing both humoral 
and cellular immune responses, here we showed that increasing the number of 
APCs at the injection site was a successful approach to obtain an improvement in 
the cellular response: a single immunization of a low dose of SAM(GM-CSF) was 
able to elicit a more potent cytotoxic T cell response.  
In this study, we selected GM-CSF as chemoattractant exclusively to reach the 
proof of concept. Indeed, caution must be taken when injecting a chemokine like 
GM-CSF as vaccine adjuvant. Various studies have been performed to evaluate 
potential mechanisms of GM-CSF-induced  immunosuppression and there is still a 
debat regarding the use of GM-CSF as an immunoadjuvant [96].  
The capacity of SAM vaccines to elicit a broad spectrum of protective immune 
response against both viral and bacterial pathogens, together with the synthetic 
methods to produce RNA and the potential to rapidly manufacture a large supply, 
make them a strong platform; moreover the possibility to further potentiate the 
cellular response by increasing the number of APCs at the injection site after a 
single immunization is of particular interest for preparedness for pandemics or 
outbreaks.  
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